Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific
Journal Title
Oral Oncology
Publication Type
Research article
Abstract
OBJECTIVES: To develop consensus on patient characteristics and disease-related factors considered in deciding treatment approaches for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) based on real-world treatment patterns in 4 territories in Asia-Pacific. METHODS: A three-round modified Delphi involving a multidisciplinary panel of HN surgeons, medical oncologists, and radiation oncologists was used. Of 41 panelists recruited, responses of 26 from Australia, Japan, Singapore, and Taiwan were analyzed. All panelists had ≥five years' experience managing LA-HNSCC patients and treated ≥15 patients with LA-HNSCC annually. RESULTS: All statements on definitions of LA-HNSCC, treatment intolerance and cisplatin dosing reached consensus. 4 of 7 statements on unresectability, 2 of 4 on adjuvant chemoradiotherapy, 7 of 13 on induction chemotherapy, 1 of 8 on absolute contraindications and 7 of 11 on relative contraindications to high-dose cisplatin did not reach consensus. In all territories except Taiwan, high-dose cisplatin was preferred in definitive and adjuvant settings for patients with no contraindications to cisplatin; weekly cisplatin (40 mg/m(2)) preferred for patients with relative contraindications to high-dose cisplatin. For Taiwan, the main treatment option was weekly cisplatin. For patients with absolute contraindications to cisplatin, carboplatin ± 5-fluorouracil or radiotherapy alone were preferred alternatives in both definitive and adjuvant settings. CONCLUSION: This multidisciplinary consensus provides insights into management of LA-HNSCC in Asia-Pacific based on patient- and disease-related factors that guide selection of treatment modality and systemic treatment. Despite strong consensus on use of cisplatin-based regimens, areas of non-consensus showed that variability in practice exists where there is limited evidence.
Publisher
Elsevier
Keywords
Humans; Squamous Cell Carcinoma of Head and Neck/drug therapy; Cisplatin/therapeutic use; *Carcinoma, Squamous Cell/pathology; *Head and Neck Neoplasms/drug therapy; Consensus; Chemoradiotherapy/adverse effects; Carboplatin; Asia; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Asia Pacific; Australia; Chemoradiotherapy; Delphi technique; Head and Neck Neoplasms*/therapy; La hnscc; Squamous Cell Carcinoma of Head and Neck; Treatment algorithms
Department(s)
Radiation Oncology
Open Access at Publisher's Site
10.1016/j.oraloncology.2023.106657
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-02-01 06:24:16
Last Modified: 2024-02-22 12:37:10

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙